Charles DeBattista

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Update on augmentation of antidepressant response in resistant depression
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA
    Curr Psychiatry Rep 7:435-40. 2005
  2. ncbi request reprint Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, 401 Quarry Road, Room 2137, Stanford, CA 94305, USA
    J Clin Psychiatry 64:1057-64. 2003
  3. ncbi request reprint The neuropsychological profile of psychotic major depression and its relation to cortisol
    Rowena G Gomez
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
    Biol Psychiatry 60:472-8. 2006
  4. ncbi request reprint A prospective trial of modafinil as an adjunctive treatment of major depression
    Charles DeBattista
    Stanford University School of Medicine, Depression Research Clinic, Stanford, CA 94305 5723, USA
    J Clin Psychopharmacol 24:87-90. 2004
  5. ncbi request reprint Augmentation and combination strategies for depression
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA 94305, USA
    J Psychopharmacol 20:11-8. 2006
  6. doi request reprint The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression
    Charles DeBattista
    Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, 401 Quarry Road, Stanford, CA 94305, USA
    J Psychiatr Res 45:64-75. 2011
  7. ncbi request reprint A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif 94305, USA
    J Clin Psychiatry 66:844-8. 2005
  8. doi request reprint Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function
    Rowena G Gomez
    Pacific Graduate School of Psychology, 405 Broadway, Redwood City, CA 94063, USA
    Psychoneuroendocrinology 34:1012-8. 2009
  9. ncbi request reprint The use of mifepristone in the treatment of neuropsychiatric disorders
    Charles DeBattista
    Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA
    Trends Endocrinol Metab 17:117-21. 2006
  10. doi request reprint A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
    Christine M Blasey
    Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
    Contemp Clin Trials 30:284-8. 2009

Detail Information

Publications28

  1. ncbi request reprint Update on augmentation of antidepressant response in resistant depression
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA
    Curr Psychiatry Rep 7:435-40. 2005
    ..We review the status of augmentation strategies in the treatment of depression...
  2. ncbi request reprint Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, 401 Quarry Road, Room 2137, Stanford, CA 94305, USA
    J Clin Psychiatry 64:1057-64. 2003
    ..In this study, we examined the utility of modafinil as an adjunct therapy to treat fatigue and sleepiness in patients with major depression who are partial responders to antidepressants...
  3. ncbi request reprint The neuropsychological profile of psychotic major depression and its relation to cortisol
    Rowena G Gomez
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
    Biol Psychiatry 60:472-8. 2006
    ..We predicted that higher cortisol levels would be associated with greater cognitive deficits...
  4. ncbi request reprint A prospective trial of modafinil as an adjunctive treatment of major depression
    Charles DeBattista
    Stanford University School of Medicine, Depression Research Clinic, Stanford, CA 94305 5723, USA
    J Clin Psychopharmacol 24:87-90. 2004
    ..Modafinil may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression...
  5. ncbi request reprint Augmentation and combination strategies for depression
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA 94305, USA
    J Psychopharmacol 20:11-8. 2006
    ..This paper summarizes the state of the evidence for commonly used augmenting strategies and explores preliminary findings for more investigational approaches...
  6. doi request reprint The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression
    Charles DeBattista
    Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, 401 Quarry Road, Stanford, CA 94305, USA
    J Psychiatr Res 45:64-75. 2011
    ..To evaluate the efficacy of rEEG(®)-guided pharmacotherapy for the treatment of depression in those circumstances where rEEG and STAR*D provided different recommendations...
  7. ncbi request reprint A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif 94305, USA
    J Clin Psychiatry 66:844-8. 2005
    ..In this double-blind trial, the efficacy of a standard dose of bupropion sustained release (SR) is evaluated in the treatment of SSRI-induced sexual dysfunction...
  8. doi request reprint Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function
    Rowena G Gomez
    Pacific Graduate School of Psychology, 405 Broadway, Redwood City, CA 94063, USA
    Psychoneuroendocrinology 34:1012-8. 2009
    ..Our study suggests that cortisol has an independent effect on verbal memory. Also, our study produced evidence of an interaction between diagnosis and cortisol on response inhibition...
  9. ncbi request reprint The use of mifepristone in the treatment of neuropsychiatric disorders
    Charles DeBattista
    Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA
    Trends Endocrinol Metab 17:117-21. 2006
    ..Preliminary studies suggest that mifepristone might have a role in the treatment of a number of neuropsychiatric disorders...
  10. doi request reprint A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
    Christine M Blasey
    Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
    Contemp Clin Trials 30:284-8. 2009
    ....
  11. ncbi request reprint A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine Stanford, CA 94305 5723, USA
    J Clin Psychopharmacol 23:27-30. 2003
    ..This prospective, open-label trial supports the use of bupropion SR in the augmentation of SSRIs and venlafaxine. Placebo controlled trials should be completed to further evaluate the efficacy of this strategy...
  12. ncbi request reprint Safety of antidepressants in the elderly
    Barbara R Sommer
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
    Expert Opin Drug Saf 2:367-83. 2003
    ..Drug interactions, side effects and particular challenges to the older patient will be described. The authors will then advise a general strategy for prescribing antidepressants...
  13. ncbi request reprint Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression
    Charles DeBattista
    Corcept Therapeutics, Menlo Park, California, USA
    Biol Psychiatry 60:1343-9. 2006
    ..Recent studies have suggested that the antiglucocorticoid, mifepristone might have a role in the treatment of PMD. The current study tested the efficacy of mifepristone treatment of the psychotic symptoms of PMD...
  14. ncbi request reprint Detecting psychotic major depression using psychiatric rating scales
    Jennifer Keller
    Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305 5723, USA
    J Psychiatr Res 40:22-9. 2006
    ..The aim of this study was to assess whether individual or clusters of psychiatric symptoms can differentiate patients with psychotic major depression (PMD) from those with nonpsychotic depression (NPMD)...
  15. ncbi request reprint The efficacy of divalproex sodium in the treatment of agitation associated with major depression
    Charles DeBattista
    Depression Research Clinic, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
    J Clin Psychopharmacol 25:476-9. 2005
    ..Thus, agitation merits investigation as a treatment target in clinical depression...
  16. ncbi request reprint Executive dysfunction in major depressive disorder
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    Expert Rev Neurother 5:79-83. 2005
    ..While few studies have examined the treatment of executive dysfunction in depression, preliminary work suggests that both pharmacologic interventions and psychosocial interventions such as problem solving therapy may be efficacious...
  17. ncbi request reprint Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Curr Drug Saf 5:263-6. 2010
    ..In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics...
  18. doi request reprint Utility of atypical antipsychotics in the treatment of resistant unipolar depression
    Charles DeBattista
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, California 94305, USA
    CNS Drugs 23:369-77. 2009
    ..This is the first medication to be FDA approved for this indication. In the present article, the usefulness of antipsychotics in the treatment of resistant unipolar depression is reviewed...
  19. pmc Depression and smoking cessation: does the evidence support psychiatric practice?
    Anna Lembke
    Department of Psychiatry, Stanford University, Stanford, CA, USA
    Neuropsychiatr Dis Treat 3:487-93. 2007
    ..More research is needed to understand the relationship between depression and quitting smoking, but current clinical evidence suggests more resiliency among depressed smokers than common clinical wisdom would dictate...
  20. ncbi request reprint Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone
    Joseph K Belanoff
    Corcept Therapeutics, Inc, Menlo Park, CA 94025, USA
    J Mol Neurosci 19:201-6. 2002
    ..Additionally, this study test the hypothesis that AD subjects with elevated cortisol at baseline will perform more poorly on neuropsychological exams that do subjects with low cortisol...
  21. doi request reprint Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial
    H George Nurnberg
    Department of Psychiatry, University of New Mexico School of Medicine, 2400 Tucker NE, MC 09 5030, Albuquerque, NM 87131 0001, USA
    JAMA 300:395-404. 2008
    ..Antidepressant-associated sexual dysfunction is a common adverse effect that frequently results in premature medication treatment discontinuation and for which no treatment has demonstrated efficacy in women...
  22. ncbi request reprint Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, and Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
    Ann Clin Psychiatry 19:153-9. 2007
    ..This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue...
  23. ncbi request reprint The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats
    Katherine L Beebe
    Corcept Therapeutics, Menlo Park, CA 94205, USA
    Behav Brain Res 171:225-9. 2006
    ..0002). Results suggest that mifepristone, a potent glucocorticoid antagonist, may both reduce and prevent olanzapine-induced weight gain in rats...
  24. ncbi request reprint An open label trial of C-1073 (mifepristone) for psychotic major depression
    Joseph K Belanoff
    Corcept Therapeutics Inc, Menlo Park, California 94025, USA
    Biol Psychiatry 52:386-92. 2002
    ..The rationale for treating patients with psychotic major depression (PMD) with glucocorticosteroid receptor (GR) antagonists is explained...
  25. ncbi request reprint Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study
    Michael E Thase
    Division of Adult Academic Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    CNS Spectr 11:93-102. 2006
    ..Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms...
  26. ncbi request reprint C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease
    Charles DeBattista
    Corcept Therapeutics, 275 Middlefield Road, Menlo Park, California 94025, USA
    Curr Alzheimer Res 2:125-9. 2005
    ..The purpose of this study is to determine the effects of glucocorticoid receptor blockade with mifepristone on cognition in Alzheimer's disease...
  27. ncbi request reprint A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:85-93. 2005
    ....
  28. ncbi request reprint HPA axis activation in major depression and response to fluoxetine: a pilot study
    Elizabeth A Young
    Department of Psychiatry, The Mental Health Research Institute, University of Michigan, 205 Zina Pitcher Place, Ann Arbor, MI 48109 0729, USA
    Psychoneuroendocrinology 29:1198-204. 2004
    ..This may reflect the greater severity of subjects with HPA axis dysregulation or the need to normalize the HPA axis with medications for optimal response...